Skip to main content

CCTG at ASTRO 2024

September 29 – October 2 Washington, DC
CCTG at ASTRO 2024

MAC23 (Oral, Plenary) - https://www.redjournal.org/article/S0360-3016(24)00764-8/fulltext

A Randomized Trial of Hypofractionated Post-Mastectomy Radiation Therapy (PMRT) in Women with Breast Reconstruction (RT CHARM, Alliance A221505)

This randomized phase III trial studies how well hypofractionated radiation therapy works in preventing recurrence in patients with stage IIa-IIIa cancer who have undergone mastectomy. Hypofractionated radiation therapy delivers higher doses of radiation therapy over a shorter period of time and may kill more tumor cells that remain after surgery and have fewer side effects.

 

CXC2 (Oral) - https://www.redjournal.org/article/S0360-3016(24)00966-0/fulltext

Comparison of Image-Guided Intensity Modulated Radiotherapy (IG-IMRT) vs. Conventional Radiotherapy (4FRT) for Locoregionally Advanced Cervical Cancer on the NRG GY006 Trial 

Despite reducing dose to organs at risk, IG-IMRT did not reduce GI or overall hematologic toxicity compared to 4FRT, possibly due to increased cisplatin delivery and different field sizes. IG-IMRT had no impact on long-term outcomes.

 

HN10 (Oral, Late Breaking Special Session) - https://www.redjournal.org/article/S0360-3016(24)03247-4/fulltext

A Phase II Single Arm Trial of Elective Volume Adjusted De-Escalation Radiotherapy (EVADER) in Patients with Low-risk HPV-related Oropharyngeal Squamous Cell Carcinoma

For patients with HPV-related OPSCC treated with radical RT, volume-reduced ENI as defined in this study can be safely performed while maintaining high efficacy with rare out-of-field regional failures. This de-escalation strategy should continue to be evaluated in rigorously conducted trials.

 

CEC3 (Oral) - https://www.redjournal.org/article/S0360-3016(24)03112-2/fulltext

Analysis of Late Cognitive Outcomes after Whole Brain Radiotherapy and Radiosurgery for Brain Metastases in the North Central Cancer Treatment Group (NCCTG) N0574 and N107C Clinical Trials

When considering participants’ last cognitive assessments, only receipt of WBRT predicted late cognitive decline in the N0574 and N107C clinical trials.

PR19 (Poster) - https://www.redjournal.org/article/S0360-3016(24)02010-8/fulltext

A Randomized Phase II Trial of High Dose-Rate (HDR) and Low Dose-Rate (LDR) Brachytherapy as Monotherapy in Localized Prostate Cancer: Analysis of Initial Arms of Canadian Cancer Trials Group PR19 (NCT02960087)

LDR brachytherapy is associated with a high prostate cancer disease control rate at 4 years, although with greater negative impact on urinary and bowel quality of life in the first 6 months. The single fraction HDR arm was discontinued early and was associated with an unacceptable prostate cancer control rate based on the early primary endpoint used in the trial.

Hematology (Oral)  https://www.redjournal.org/article/S0360-3016(24)03041-4/fulltext

Beyond Involved-Site Radiotherapy: NRG, COG, Alliance, ECOG-ACRIN, SWOG and CCTG Consensus Nomenclature for Radiation Targets on NCTN Lymphoma Trials

NRG Oncology, COG, SWOG, Alliance, ECOG-ACRIN, and CCTG propose a consensus nomenclature for contemporary RT target volumes to be used on lymphoma protocols. Recommendations for using these target volumes are beyond the scope of this work and require comparative studies and/or in-depth analysis of patterns of relapse.